Literature DB >> 14593737

The mitotic checkpoint: a signaling pathway that allows a single unattached kinetochore to inhibit mitotic exit.

Gordon K Chan1, Tim J Yen.   

Abstract

The mitotic checkpoint is a failsafe mechanism for the cell to ensure accurate chromosome segregation during mitosis. Mutations in genes encoding essential checkpoint proteins lead to chromosome instability and promote carcinogenesis. The BUB and MAD genes are essential components of the mitotic checkpoint pathway. BUB and MAD inhibit the ubiquitin ligase activity of the Anaphase Promoting Complex/Cyclosome (APC/C) during mitosis to ensure cells with unaligned chromosomes do not prematurely enter anaphase. Two models explain how the APC/C is inhibited by the checkpoint. The Sequestration Model postulates that Mad2 and BubR1 bind and sequester Cdc20, an APC/C activator, away from APC/C so substrates whose destruction drives mitotic exit are no longer ubiquitinated. In this model, the unattached kinetochore is postulated to catalytically convert Mad2 to a form that binds Cdc20. In the Direct Inhibition Model, the Mitotic Checkpoint Complex (MCC) consisting of BubR1, Bub3, Mad2 and Cdc20 binds and inhibits the APC/C independently of the kinetochore. However, the "wait anaphase" signal generated by unattached kinetochores sensitizes the APC/C to prolonged inhibition by the MCC. A single unattached kinetochore is proposed to amplify the "wait anaphase" signal through a kinase cascade involving checkpoint kinases such as hBubR1, hBub1 and Mps1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593737

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN: 1087-2957


  25 in total

1.  Modulation of the anti-cancer efficacy of microtubule-targeting agents by cellular growth conditions.

Authors:  Jay F Dorsey; Melissa L Dowling; Mijin Kim; Ranh Voong; Lawrence J Solin; Gary D Kao
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

2.  In vivo quantitative studies of dynamic intracellular processes using fluorescence correlation spectroscopy.

Authors:  Zifu Wang; Jagesh V Shah; Michael W Berns; Don W Cleveland
Journal:  Biophys J       Date:  2006-04-07       Impact factor: 4.033

3.  Dose-dependent effects of stable cyclin B1 on progression through mitosis in human cells.

Authors:  Frank Wolf; Cornelia Wandke; Nina Isenberg; Stephan Geley
Journal:  EMBO J       Date:  2006-05-25       Impact factor: 11.598

4.  Loading of the 3F3/2 antigen onto kinetochores is dependent on the ordered assembly of the spindle checkpoint proteins.

Authors:  Oi Kwan Wong; Guowei Fang
Journal:  Mol Biol Cell       Date:  2006-08-02       Impact factor: 4.138

Review 5.  Cenp-F (mitosin) is more than a mitotic marker.

Authors:  Asta Varis; Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2006-03-25       Impact factor: 4.316

6.  Detection of Significant Pneumococcal Meningitis Biomarkers by Ego Network.

Authors:  Qian Wang; Zhifeng Lou; Liansuo Zhai; Haibin Zhao
Journal:  Indian J Pediatr       Date:  2017-03-01       Impact factor: 1.967

7.  Human enhancer of invasion-cluster, a coiled-coil protein required for passage through mitosis.

Authors:  Margret B Einarson; Edna Cukierman; Duane A Compton; Erica A Golemis
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

8.  Impact on genetic networks in human macrophages by a CCR5 strain of human immunodeficiency virus type 1.

Authors:  Carter R Coberley; James J Kohler; Joseph N Brown; Joseph T Oshier; Henry V Baker; Michael P Popp; John W Sleasman; Maureen M Goodenow
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  The vitamin D3 transcriptomic response in skin cells derived from the Atlantic bottlenose dolphin.

Authors:  Blake C Ellis; Sebastiano Gattoni-Celli; Annalaura Mancia; Mark S Kindy
Journal:  Dev Comp Immunol       Date:  2009-03-21       Impact factor: 3.636

10.  BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.

Authors:  Y-K Lee; E Choi; M A Kim; P-G Park; N-H Park; H Lee
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.